Carlo Maley

We are excited to announce a new clinical trial - adaptive therapy for metastatic ER+ breast cancer at Mayo Clinic AZ (NCT06525766). Adaptive therapy manages the evolution of the cancer to extend survival time and reduce toxicity (improve quality of life). bit.ly/4cehaWe

I'm looking forward to the big AACR Cancer Evolution conference in Albuquerque Dec. 4-6: aacr.org/meeting/aacr-s…

We are hiring a postdoc to profile the evolvability of tumors in longitudinal samples from three clinical trials as part of the ARPA-H ADAPT program. This is essentially an evolutionary bioinformatics position. If you are interested, please apply here ASAP apply.interfolio.com/172521

If you are interested in our research about discovering species with extremely low cancer rates or using ideas from integrated pest management to improve cancer therapy, ASU has a new podcast Lab Coat Optional that featured my work in an episode: youtube.com/watch?v=P8r08u…

@LetsTalkFngC We are researching what we can learn about preventing and treating cancer through studying other animals (e.g. elephants). As part of our project we would like to have patient advocates and science communicators involved. Would you be interested?

We just published a review of lessons farmers have learned for how to control pesticide resistance from evolving, and how to apply those to oncology to prevent cancers from evolving therapeutic resistance: bit.ly/48OfFdX

We are excited to announce that a 10 year project to gather and analyze veterinary necropsy data to discover cancer prevalence across (292) vertebrate species has finally been published open access in Cancer Discovery @aacr bit.ly/40nCqmH #componc #cancer

I'm going to try to migrate to Bluesky as much as possible. Please follow me there at @cmaley.bsky.social

@Kevinsecto I'm trying to get in touch with you (by email or slack) about the PPF search committee. Is that something you want to do?

DeGregori: This is not just a problem for cancers, but for many other disease as well #CancerEvoEco24

DeGregori: Age and smoking perturb tissue leading to harmful clonal expansions that further perturb the tissue... vicious cycle #CancerEvoEco24

DeGregori: Some evidence that clones with NF1 mutation make the lung more permeable to carcinogens #CancerEvoEco24

DeGregori: Can treat mice with cigarette smoke (used CRISPR to inactivate particular genes in a few cells). Smoking increased the frequency of the mutant clones. Looks like knocking out NF1 led to more progenitor cells (though not sure if they are protenitors yet) #CancerEvoEco24

DeGregori: Saw patient specific mutations in particular genes (may be due to individual differences in tissue level selection or to exposures) #CancerEvoEco24

DeGregori: Got up to 30 different small pieces of lung tissue from the PEACE autopsies. Saw different mutations in the same gene in different locations within the same individual. #CancerEvoEco24

DeGregori: Smokers have a higher fraction of lung tissue (9%) occupied by the mutations in the panel gene, compared to the never smokers (2%) #CancerEvoEco24

DeGregori: Faiz Jabbar combined dN/dS with variant allele frequency as both signals of selection. TP53, Notch1, NF1, and ERBB4 were the top selected genes in the normal lung tissue - in smokers #CancerEvoEco24

DeGregori: A mutation can be adaptive in a normal tissue but not contribute to malignancies (as was seen in a lot of other studies of normal tissues) #CancerEvoEco24

DeGregori: The mutations that promote clonal expansion are not the mutations observed in cancer (even if you only look at COSMIC annotated mutations) #CancerEvoEco24

DeGregori: Particularly in the never smokers, saw mutations in KRAS and EGFR, but not the ones that show up in the cancers #CancerEvoEco24